Tafasitamab Plus Lenalidomide Bests Standard Treatments in Key High-Risk R/R DLBCL Subgroups
June 6th 2022According to Grzegorz S. Nowakowski, MD, results from a subgroup analysis of the observational RE-MIND study may aid in contextualizing therapy options for treating patients with relapsed or refractory diffuse large B-cell lymphoma.
Read More
Adjuvant Pembrolizumab Significantly Improves DMFS and RFS in Patients with Stage II Melanoma
June 5th 2022Adjuvant pembrolizumab improved distant metastasis-free survival and longer follow up for recurrence-free survival in patients with resected stage IIB or stage IIC melanoma, according to data discussed at the 2022 ASCO Annual Meeting.
Read More
Benefit of Alpelisib/Fulvestrant Combo in HR+/HER- Breast Cancer Confirmed With Biomarker Analysis
June 5th 2022Combination of alpelisib and fulvestrant shows clinical benefit in patients with hormone receptor–positive, HER2-negative advanced breast cancer regardless of gene mutation status, according to a retrospective biomarker analysis.
Read More
Transplant and Lenalidomide Maintenance Improves PFS in Newly Diagnosed Myeloma After RVd Treatment
June 5th 2022At the 2022 ASCO Annual Meeting findings from the phase, 3 DETERMINATION trial showed off the survival benefit when adding autologous stem cell transplant and lenalidomide maintenance after RVd treatment for patients with newly diagnosed multiple myeloma.
Read More
Daratumumab and Carfilzomib Quadruplet and Tandem Transplant Appears Feasible for High-Risk Myeloma
June 5th 2022Based on a 2022 ASCO Annual Meeting presentation given by Cyrille Touzeau, MD, PhD, the IFM 2018-04 study confirms the efficacy and feasibility of the quadruplet induction regimen Dara-KRd in high-risk, transplant-eligible patients with multiple myeloma.
Read More
Larotrectinib Continues to Demonstrate Durable Responses in TRK Fusion Cancer
June 5th 2022According to Alexander E. Drilon, MD, larotrectinib, regardless of tumor type in adult and pediatric and adult cancers with an NTRK fusion, can demonstrate very robust responses and durable responses.
Read More
Daratumumab Added to RVd Achieved MRD Negativity, PFS Improvement in Newly Diagnosed Myeloma
June 5th 2022Among patients with newly diagnosed, transplant-eligible myeloma treated in a phase 2 study, induction and consolidation with daratumumab plus the RVd regimen outperformed RVd alone in terms of minimal residual disease and progression-free survival.
Read More
Treatment with ribociclib and an alternate endocrine therapy after progression on a prior CDK4/6 inhibitor improved progression-free survival over placebo and endocrine therapy in patients with HR-positive, HER2-negative unresectable or metastatic breast cancer, according to results of the randomized phase 2 MAINTAIN trial.
Read More
Patritumab Deruxtecan Elicits Promising Response in HER3-Expressing mBC
June 4th 2022According to Ian E. Krop, MD, PhD, patritumab deruxtecan is responsible for producing clinically meaningful and durable antitumor activity in patients with HER3-expressing metastatic breast cancer, warranting further research.
Read More
Bispecific Antibody Triplet Regimen Induces 100% Response Rate in R/R FL
June 4th 2022Findings from an arm of the EPCORE NHL-2 trial, presented at the 2022 ASCO Annual meeting, showed promising antitumor activity in patients with relapsed or refractory follicular lymphoma on subcutaneous epcoritamab combined with rituximab and lenalidomide.
Read More
DESTINY-Breast03 Update Reinforces Safety of Trastuzumab Deruxtecan in Metastatic Breast Cancer
June 4th 2022A safety follow-up analysis of the randomized phase 3 DESTINY-Breast03 study reinforced the risk-benefit profile of trastuzumab deruxtecan compared with trastuzumab emtansine in patients with HER2-positive unresectable or metastatic breast cancer
Read More
Magrolimab Plus Azacitidine Treatment Correlates With Manageable Anemia in High-Risk MDS, AML
June 4th 2022According to , results from a phase 1 study support that on-target magrolimab-mediated anemia is manageable in patients with high-risk myelodysplastic syndrome and acute myeloid leukemia.
Read More
BTX-1188 Undergoing Evaluation in AML, Solid Tumors After Showing Promise in Preclinical Data
June 4th 2022BTX-1188 could prevent systemic inflammatory dose-limiting toxicities that are usually attributed to pure GSPT1 degradation due to its immunomodulatory properties from the IKZF1/3 degradation.
Read More
Acalabrutinib-Based Regimens Continue to Top Obinutuzumab Plus Chemotherapy in Treatment-Naïve CLL
June 4th 2022With roughly 5 years of follow-up, outcomes were more favorable with acalabrutinib with or without obinutuzumab vs obinutuzumab and chlorambucil in patients with treatment-naïve chronic lymphocytic leukemia.
Read More